title: [The role of surgery in the treatment of prolactinomas].
abstract: METHODS
  Almost all prolactinomas are operated through a transsphenoidal route, even in case of significant suprasellar extension or intracavernous invasion. Since 1996, we use the only endonasal route which is easier, quicker, less haemorrhagic and less aggressive than the sublabial one. If the removal of a large macroadenoma cannot be completed (50-70% of cases), a second procedure, usually transsphenoidal, is performed a few weeks later.
  
  
  METHODS
  Microprolactinomas: usually surgery is proposed as soon as medical treatment is not well tolerated or if the patient wishes to be pregnant. Macroprolactinomas: bromocriptine or quinagolide are sometimes prescribed in a first stage. Surgery beeing indicated in case of inefficacy or intolerance of the medical treatment, or in emergency due to an acute visual pathways compression (tumoral necrosis). Giant adenomas (= 30-40 mm): usually dopaminergic agonists allow a tumoral volume reduction and assure a limitation of visual risks due to rapid decompression of visual pathways. Exceptionally, medical treatment leads to a complete regression of the adenoma.
  
  
  RESULTS
  Morbidity of transsphenoidal procedures: insipidus diabetes: transient 5-15%, definitive: 1-2%; septal perforation: 3-5%; rhinorrhea: 5%; visual aggravation: 2%. The most frequent complaint for patients operated through sublabial route is gum and dental pain, non-existent with endonasal procedures. Operative mortality: 0-1.7% (0% in our series). In men, normalization of prolactinemia is linked to the tumoral volume: 90-100% in case of microprolactinoma, 30-35% for enclosed macroprolactinomas, 0-5% for invasive macroprolactinomas. Conventional, conformational or stereotactic radiotherapy can be useful in case of contraindication to surgery and failure of medical treatment.
authors.affiliation: Service de neurochirurgie, centre hospitalier Sainte-Anne, 1, rue Cabanis, 75014 Paris, France. roux@chsa.broca.inserm.fr
authors.forename: F X
authors.initials: FX
authors.lastname: Roux
authors.forename: F
authors.initials: F
authors.lastname: Nataf
authors.forename: P
authors.initials: P
authors.lastname: Page
authors.forename: B
authors.initials: B
authors.lastname: Devaux
authors.forename: F
authors.initials: F
authors.lastname: Brami
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D010911:Pituitary Neoplasms / Q000453:epidemiology / Q000601:surgery*; D011183:Postoperative Complications; D015175:Prolactinoma / Q000453:epidemiology / Q000601:surgery*; D013514:Surgical Procedures, Operative / Q000009:adverse effects / Q000379:methods